These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A. Neoplasia; 2012 Feb 01; 14(2):121-30. PubMed ID: 22431920 [Abstract] [Full Text] [Related]
16. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R. World J Gastroenterol; 2012 Nov 21; 18(43):6226-34. PubMed ID: 23180942 [Abstract] [Full Text] [Related]
17. [The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell]. Li SS, Zhang X, Xu J, Xie L, Qiu Y, Shu X, Tian Y. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Sep 21; 23(18):817-20, 823. PubMed ID: 20120857 [Abstract] [Full Text] [Related]